Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2016, Article ID 1459394, 16 pages
http://dx.doi.org/10.1155/2016/1459394
Review Article

Adjuvants: Classification, Modus Operandi, and Licensing

1Department of Microbiology, Immunology and Parasitology, Federal University of São Paulo (UNIFESP/EPM), Rua Botucatu, 4° Andar, 04023-062 São Paulo, SP, Brazil
2Department of Parasitology, Institute of Biomedical Sciences, University of São Paulo, Avenida Lineu Prestes 1374, 05508-000 São Paulo, SP, Brazil
3Instituto de Investigação em Imunologia (iii), 01246-903 São Paulo, SP, Brazil

Received 18 February 2016; Revised 2 April 2016; Accepted 11 April 2016

Academic Editor: Lenin Pavon

Copyright © 2016 Juliana de Souza Apostólico et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. C. Cox and A. R. Coulter, “Adjuvants—a classification and review of their modes of action,” Vaccine, vol. 15, no. 3, pp. 248–256, 1997. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Ramon, “Sur la toxine et sur I'anatoxine diphtheriques,” Annales de l'Institut Pasteur, vol. 38, pp. 1–10, 1924. View at Google Scholar
  3. A. D. Pasquale, S. Preiss, F. Silva, and N. Garçon, “Vaccine adjuvants: from 1920 to 2015 and beyond,” Vaccines, vol. 3, no. 2, pp. 320–343, 2015. View at Publisher · View at Google Scholar
  4. A. T. Glenny, C. G. Pope, H. Waddington, and U. Wallace, “Immunological notes. XVII–XXIV,” The Journal of Pathology and Bacteriology, vol. 29, no. 1, pp. 31–40, 1926. View at Publisher · View at Google Scholar
  5. E. L. Opie, “An experimental study of protective inoculation with heat killed tubercle bacilli,” The Journal of Experimental Medicine, vol. 66, no. 6, pp. 761–788, 1937. View at Publisher · View at Google Scholar
  6. B. Guy, “The perfect mix: recent progress in adjuvant research,” Nature Reviews Microbiology, vol. 5, no. 7, pp. 505–517, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Awate, L. A. Babiuk, and G. Mutwiri, “Mechanisms of action of adjuvants,” Frontiers in Immunology, vol. 4, article 114, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. S. G. Reed, M. T. Orr, and C. B. Fox, “Key roles of adjuvants in modern vaccines,” Nature Medicine, vol. 19, no. 12, pp. 1597–1608, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. R. L. Coffman, A. Sher, and R. A. Seder, “Vaccine adjuvants: putting innate immunity to work,” Immunity, vol. 33, no. 4, pp. 492–503, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Singh and D. T. O'Hagan, “Recent advances in vaccine adjuvants,” Pharmaceutical Research, vol. 19, no. 6, pp. 715–728, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Pashine, N. M. Valiante, and J. B. Ulmer, “Targeting the innate immune response with improved vaccine adjuvants,” Nature Medicine, vol. 11, no. 4, pp. S63–S68, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. N. Goto and K. Akama, “Histopathological studies of reactions in mice injected with aluminum-adsorbed tetanus toxoid,” Microbiology and Immunology, vol. 26, no. 12, pp. 1121–1132, 1982. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Olive, “Pattern recognition receptors: sentinels in innate immunity and targets of new vaccine adjuvants,” Expert Review of Vaccines, vol. 11, no. 2, pp. 237–256, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. E. B. Lindblad, “Aluminium compounds for use in vaccines,” Immunology and Cell Biology, vol. 82, no. 5, pp. 497–505, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. R. K. Gupta, B. E. Rost, E. Relyveld, and G. R. Siber, “Adjuvant properties of aluminum and calcium compounds,” Pharmaceutical Biotechnology, vol. 6, pp. 229–248, 1995. View at Publisher · View at Google Scholar · View at Scopus
  16. V. E. Schijns, “Immunological concepts of vaccine adjuvant activity,” Current Opinion in Immunology, vol. 12, no. 4, pp. 456–463, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Hutchison, R. A. Benson, V. B. Gibson, A. H. Pollock, P. Garside, and J. M. Brewer, “Antigen depot is not required for alum adjuvanticity,” The FASEB Journal, vol. 26, no. 3, pp. 1272–1279, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. B. N. Lambrecht, M. Kool, M. A. M. Willart, and H. Hammad, “Mechanism of action of clinically approved adjuvants,” Current Opinion in Immunology, vol. 21, no. 1, pp. 23–29, 2009. View at Publisher · View at Google Scholar
  19. P. Marrack, A. S. McKee, and M. W. Munks, “Towards an understanding of the adjuvant action of aluminium,” Nature Reviews Immunology, vol. 9, no. 4, pp. 287–293, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Kool, T. Soullié, M. Van Nimwegen et al., “Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells,” The Journal of Experimental Medicine, vol. 205, no. 4, pp. 869–882, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. S. C. Eisenbarth, O. R. Colegio, W. O'Connor Jr., F. S. Sutterwala, and R. A. Flavell, “Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants,” Nature, vol. 453, no. 7198, pp. 1122–1126, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. T. R. Ghimire, R. A. Benson, P. Garside, and J. M. Brewer, “Alum increases antigen uptake, reduces antigen degradation and sustains antigen presentation by DCs in vitro,” Immunology Letters, vol. 147, no. 1-2, pp. 55–62, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. A. K. Bajaj, S. C. Gupta, R. K. Pandey, K. Misra, S. Rastogi, and A. K. Chatterji, “Aluminium contact sensitivity,” Contact Dermatitis, vol. 37, no. 6, pp. 307–308, 1997. View at Google Scholar · View at Scopus
  24. A. Billiau and P. Matthys, “Modes of action of Freund's adjuvants in experimental models of autoimmune diseases,” Journal of Leukocyte Biology, vol. 70, no. 6, pp. 849–860, 2001. View at Google Scholar · View at Scopus
  25. P. P. Leenaars, C. F. Hendriksen, W. A. de Leeuw et al., “The production of polyclonal antibodies in laboratory animals. the report and recommendations of ECVAM workshop 35,” Alternatives to Laboratory Animals, vol. 27, no. 1, pp. 79–102, 1999. View at Google Scholar
  26. CCAC, Guidelines on Antibody Production, Canadian Council on Animal Care, 2002.
  27. J. E. Salk and A. M. Laurent, “The use of adjuvants in studies on influenza immunization. I. Measurements in monkeys of the dimensions of antigenicity of virus-mineral oil emulsions,” The Journal of Experimental Medicine, vol. 95, no. 5, pp. 429–447, 1952. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Mussener, L. Klareskog, J. C. Lorentzen, and S. Kleinau, “TNF-α dominates cytokine mRNA expression in lymphoid tissues of rats developing collagen- and oil-induced arthritis,” Scandinavian Journal of Immunology, vol. 42, no. 1, pp. 128–134, 1995. View at Publisher · View at Google Scholar · View at Scopus
  29. L. H. Miller, A. Saul, and S. Mahanty, “Revisiting Freund's incomplete adjuvant for vaccines in the developing world,” Trends in Parasitology, vol. 21, no. 9, pp. 412–414, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. D. T. O'Hagan, A. Wack, and A. Podda, “MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development?” Clinical Pharmacology and Therapeutics, vol. 82, no. 6, pp. 740–744, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Vesikari, M. Pellegrini, A. Karvonen et al., “Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant,” Pediatric Infectious Disease Journal, vol. 28, no. 7, pp. 563–571, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. D. T. O'Hagan, G. S. Ott, G. Van Nest, R. Rappuoli, and G. Del Giudice, “The history of MF59® adjuvant: a phoenix that arose from the ashes,” Expert Review of Vaccines, vol. 12, no. 1, pp. 13–30, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. T. Vesikari, M. Knuf, P. Wutzler et al., “Oil-in-water emulsion adjuvant with influenza vaccine in young children,” The New England Journal of Medicine, vol. 365, no. 15, pp. 1406–1416, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. H. I. Nakaya, E. Clutterbuck, D. Kazmin et al., “Systems biology of immunity to MF59-adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood,” Proceedings of the National Academy of Sciences, vol. 113, no. 7, pp. 1853–1858, 2016. View at Publisher · View at Google Scholar
  35. T. C. Heineman, M. L. Clements-Mann, G. A. Poland et al., “A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant,” Vaccine, vol. 17, no. 22, pp. 2769–2778, 1999. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Dupuis, D. M. McDonald, and G. Ott, “Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice,” Vaccine, vol. 18, no. 5-6, pp. 434–439, 1999. View at Publisher · View at Google Scholar · View at Scopus
  37. I. Stephenson, R. Bugarini, K. G. Nicholson et al., “Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy,” Journal of Infectious Diseases, vol. 191, no. 8, pp. 1210–1215, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Seubert, E. Monaci, M. Pizza, D. T. O'hagan, and A. Wack, “The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells,” The Journal of Immunology, vol. 180, no. 8, pp. 5402–5412, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. E. De Gregorio, E. Caproni, and J. B. Ulmer, “Vaccine adjuvants: mode of action,” Frontiers in Immunology, vol. 4, article 214, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. F. Mosca, E. Tritto, A. Muzzi et al., “Molecular and cellular signatures of human vaccine adjuvants,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 30, pp. 10501–10506, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Vono, M. Taccone, P. Caccin et al., “The adjuvant MF59 induces ATP release from muscle that potentiates response to vaccination,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 52, pp. 21095–21100, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. N. Garçon, D. W. Vaughn, and A. M. Didierlaurent, “Development and evaluation of AS03, an adjuvant system containing α-tocopherol and squalene in an oil-in-water emulsion,” Expert Review of Vaccines, vol. 11, no. 3, pp. 349–366, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Morel, A. Didierlaurent, P. Bourguignon et al., “Adjuvant system AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity,” Vaccine, vol. 29, no. 13, pp. 2461–2473, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. J. A. Stoute, M. Slaoui, D. G. Heppner et al., “A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria,” The New England Journal of Medicine, vol. 336, no. 2, pp. 86–91, 1997. View at Publisher · View at Google Scholar · View at Scopus
  45. J. Díez-Domingo, M. Garcés-Sanchez, J.-M. Baldó et al., “Immunogenicity and safety of H5N1 A/vietnam/1194/2004 (clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase II, randomized, open, controlled study,” Pediatric Infectious Disease Journal, vol. 29, no. 6, pp. e35–e46, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. A. C. Martinez, I. S. De La Cueva, P. Boutet, C. V. Abeele, I. Smolenov, and J.-M. Devaster, “A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months,” Human Vaccines and Immunotherapeutics, vol. 10, no. 7, pp. 1959–1968, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. C. Muratori, R. Bona, and M. Federico, “Lentivirus-based virus-like particles as a new protein delivery tool,” Methods in Molecular Biology, vol. 614, pp. 111–124, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. C. Huret, D. Desjardins, M. Miyalou et al., “Recombinant retrovirus-derived virus-like particle-based vaccines induce hepatitis C virus-specific cellular and neutralizing immune responses in mice,” Vaccine, vol. 31, no. 11, pp. 1540–1547, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. N. Kushnir, S. J. Streatfield, and V. Yusibov, “Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development,” Vaccine, vol. 31, no. 1, pp. 58–83, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. L. Zhang, D. Pasquale, M. Le, R. Patel, and S. Mehdi, “Isolated splenic metastasis in a patient with two distinct genitourinary malignancies,” Journal of Community and Supportive Oncology, vol. 13, no. 6, pp. 229–230, 2015. View at Google Scholar
  51. C. M. Bosio, B. D. Moore, K. L. Warfield et al., “Ebola and Marburg virus-like particles activate human myeloid dendritic cells,” Virology, vol. 326, no. 2, pp. 280–287, 2004. View at Publisher · View at Google Scholar · View at Scopus
  52. D. M. Da Silva, S. C. Fausch, J. S. Verbeek, and W. M. Kast, “Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fcγ receptors and contributes to acquisition of T cell immunity,” The Journal of Immunology, vol. 178, no. 12, pp. 7587–7597, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. C. Dalba, B. Bellier, N. Kasahara, and D. Klatzmann, “Replication-competent vectors and empty virus-like particles: new retroviral vector designs for cancer gene therapy or vaccines,” Molecular Therapy, vol. 15, no. 3, pp. 457–466, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. D. M. Smith, J. K. Simon, and J. R. Baker Jr., “Applications of nanotechnology for immunology,” Nature Reviews Immunology, vol. 13, no. 8, pp. 592–605, 2013. View at Publisher · View at Google Scholar · View at Scopus
  55. L. Buonaguro, L. Racioppi, M. L. Tornesello et al., “Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A,” Antiviral Research, vol. 54, no. 3, pp. 189–201, 2002. View at Publisher · View at Google Scholar · View at Scopus
  56. R. Zurbriggen, “Immunostimulating reconstituted influenza virosomes,” Vaccine, vol. 21, no. 9-10, pp. 921–924, 2003. View at Publisher · View at Google Scholar · View at Scopus
  57. M. J. Copland, T. Rades, N. M. Davies, and M. A. Baird, “Lipid based particulate formulations for the delivery of antigen,” Immunology and Cell Biology, vol. 83, no. 2, pp. 97–105, 2005. View at Publisher · View at Google Scholar · View at Scopus
  58. M. A. Morse, R. Chapman, J. Powderly et al., “Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with toll-like receptor stimulation to induce immunity to self-antigens in cancer patients,” Clinical Cancer Research, vol. 17, no. 14, pp. 4844–4853, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. D. Felnerova, J.-F. Viret, R. Glück, and C. Moser, “Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs,” Current Opinion in Biotechnology, vol. 15, no. 6, pp. 518–529, 2004. View at Publisher · View at Google Scholar · View at Scopus
  60. P. Elamanchili, C. M. E. Lutsiak, S. Hamdy, M. Diwan, and J. Samuel, “‘Pathogen-mimicking’ nanoparticles for vaccine delivery to dendritic cells,” Journal of Immunotherapy, vol. 30, no. 4, pp. 378–395, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. F. Danhier, E. Ansorena, J. M. Silva, R. Coco, A. Le Breton, and V. Préat, “PLGA-based nanoparticles: an overview of biomedical applications,” Journal of Controlled Release, vol. 161, no. 2, pp. 505–522, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. L. J. Cruz, P. J. Tacken, R. Fokkink et al., “Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro,” Journal of Controlled Release, vol. 144, no. 2, pp. 118–126, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. E. MacHo Fernandez, J. Chang, J. Fontaine et al., “Activation of invariant Natural Killer T lymphocytes in response to the α-galactosylceramide analogue KRN7000 encapsulated in PLGA-based nanoparticles and microparticles,” International Journal of Pharmaceutics, vol. 423, no. 1, pp. 45–54, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. J. K. Vasir and V. Labhasetwar, “Biodegradable nanoparticles for cytosolic delivery of therapeutics,” Advanced Drug Delivery Reviews, vol. 59, no. 8, pp. 718–728, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. H. Shen, A. L. Ackerman, V. Cody et al., “Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles,” Immunology, vol. 117, no. 1, pp. 78–88, 2006. View at Publisher · View at Google Scholar · View at Scopus
  66. T. T. Beaudette, E. M. Bachelder, J. A. Cohen et al., “In vivo studies on the effect of co-encapsulation of CpG DNA and antigen in acid-degradable microparticle vaccines,” Molecular Pharmaceutics, vol. 6, no. 4, pp. 1160–1169, 2009. View at Publisher · View at Google Scholar · View at Scopus
  67. S. de Jong, G. Chikh, L. Sekirov et al., “Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN,” Cancer Immunology, Immunotherapy, vol. 56, no. 8, pp. 1251–1264, 2007. View at Publisher · View at Google Scholar · View at Scopus
  68. M. Manish, A. Rahi, M. Kaur, R. Bhatnagar, and S. Singh, “A single-dose PLGA encapsulated protective antigen domain 4 nanoformulation protects mice against Bacillus anthracis spore challenge,” PLoS ONE, vol. 8, no. 4, Article ID e61885, 2013. View at Publisher · View at Google Scholar · View at Scopus
  69. J. J. Moon, H. Suh, M. E. Polhemus, C. F. Ockenhouse, A. Yadava, and D. J. Irvine, “Antigen-displaying lipid-enveloped PLGA nanoparticles as delivery agents for a Plasmodium vivax malaria vaccine,” PLoS ONE, vol. 7, no. 2, Article ID e31472, 2012. View at Publisher · View at Google Scholar · View at Scopus
  70. C. Thomas, A. Rawat, L. Hope-Weeks, and F. Ahsan, “Aerosolized PLA and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to hepatitis B vaccine,” Molecular Pharmaceutics, vol. 8, no. 2, pp. 405–415, 2011. View at Publisher · View at Google Scholar · View at Scopus
  71. L. Alexopoulou, A. C. Holt, R. Medzhitov, and R. A. Flavell, “Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3,” Nature, vol. 413, no. 6857, pp. 732–738, 2001. View at Publisher · View at Google Scholar · View at Scopus
  72. M. S. Duthie, H. P. Windish, C. B. Fox, and S. G. Reed, “Use of defined TLR ligands as adjuvants within human vaccines,” Immunological Reviews, vol. 239, no. 1, pp. 178–196, 2011. View at Publisher · View at Google Scholar · View at Scopus
  73. H. Kato, O. Takeuchi, S. Sato et al., “Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses,” Nature, vol. 441, no. 1, pp. 101–105, 2006. View at Publisher · View at Google Scholar · View at Scopus
  74. M. P. Longhi, C. Trumpfheller, J. Idoyaga et al., “Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant,” The Journal of Experimental Medicine, vol. 206, no. 7, pp. 1589–1602, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. G. M. Davey, M. Wojtasiak, A. I. Proietto, F. R. Carbone, W. R. Heath, and S. Bedoui, “Cutting edge: priming of CD8 T cell immunity to herpes simplex virus type 1 requires cognate TLR3 expression in vivo,” Journal of Immunology, vol. 184, no. 5, pp. 2243–2246, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. O. Schulz, S. S. Diebold, M. Chen et al., “Toll-like receptor 3 promotes cross-priming to virus-infected cells,” Nature, vol. 433, no. 7028, pp. 887–892, 2005. View at Publisher · View at Google Scholar · View at Scopus
  77. C. Trumpfheller, M. Caskey, G. Nchinda et al., “The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 7, pp. 2574–2579, 2008. View at Publisher · View at Google Scholar · View at Scopus
  78. J. S. Apostólico, S. B. Boscardin, M. M. Yamamoto et al., “HIV envelope trimer specific immune response is influenced by different adjuvant formulations and heterologous prime-boost,” PLOS ONE, vol. 11, no. 1, Article ID e0145637, 2016. View at Publisher · View at Google Scholar
  79. H. R. Henriques, E. V. Rampazo, A. J. S. Gonçalves et al., “Targeting the non-structural protein 1 from dengue virus to a dendritic cell population confers protective immunity to lethal virus challenge,” PLoS Neglected Tropical Diseases, vol. 7, no. 7, article e2330, 2013. View at Google Scholar · View at Scopus
  80. K. Tewari, B. J. Flynn, S. B. Boscardin et al., “Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and αDEC-CSP in non human primates,” Vaccine, vol. 28, no. 45, pp. 7256–7266, 2010. View at Publisher · View at Google Scholar · View at Scopus
  81. G. Forte, A. Rega, S. Morello et al., “Polyinosinic-polycytidylic acid limits tumor outgrowth in a mouse model of metastatic lung cancer,” The Journal of Immunology, vol. 188, no. 11, pp. 5357–5364, 2012. View at Publisher · View at Google Scholar · View at Scopus
  82. T. Nagato, Y.-R. Lee, Y. Harabuchi, and E. Celis, “Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 t-cell responses against established tumors,” Clinical Cancer Research, vol. 20, no. 5, pp. 1223–1234, 2014. View at Publisher · View at Google Scholar · View at Scopus
  83. C. Stahl-Hennig, M. Eisenblätter, E. Jasny et al., “Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques,” PLoS Pathogens, vol. 5, no. 4, Article ID e1000373, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. D. Ruane, Y. Do, L. Brane et al., “A dendritic cell targeted vaccine induces long-term HIV-specific immunity within the gastrointestinal tract,” Mucosal Immunology, 2016. View at Publisher · View at Google Scholar
  85. V. Mata-Haro, C. Cekic, M. Martin, P. M. Chilton, C. R. Casella, and T. C. Mitchell, “The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4,” Science, vol. 316, no. 5831, pp. 1628–1632, 2007. View at Publisher · View at Google Scholar · View at Scopus
  86. M. Hopkins, B. G. Lees, D. G. Richardson, S. R. Woroniecki, and A. W. Wheeler, “Standardisation of glutaraldehyde-modified tyrosine-adsorbed tree pollen vaccines containing the Th1-inducing adjuvant, monophosphoryl lipid A (MPL),” Allergologia et Immunopathologia, vol. 29, no. 6, pp. 245–254, 2001. View at Publisher · View at Google Scholar · View at Scopus
  87. M. S. Mitchell, “Perspective on allogeneic melanoma lysates in active specific immunotherapy,” Seminars in Oncology, vol. 25, no. 6, pp. 623–635, 1998. View at Google Scholar · View at Scopus
  88. A. M. Didierlaurent, S. Morel, L. Lockman et al., “AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity,” The Journal of Immunology, vol. 183, no. 10, pp. 6186–6197, 2009. View at Publisher · View at Google Scholar · View at Scopus
  89. J. W. Huleatt, A. R. Jacobs, J. Tang et al., “Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity,” Vaccine, vol. 25, no. 4, pp. 763–775, 2007. View at Publisher · View at Google Scholar · View at Scopus
  90. J. Garaude, A. Kent, N. van Rooijen, and J. M. Blander, “Simultaneous targeting of toll- and nod-like receptors induces effective tumor-specific immune responses,” Science Translational Medicine, vol. 4, no. 120, Article ID 120ra16, 2012. View at Publisher · View at Google Scholar · View at Scopus
  91. Y. Zhao, J. Yang, J. Shi et al., “The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus,” Nature, vol. 477, no. 7366, pp. 596–600, 2011. View at Publisher · View at Google Scholar · View at Scopus
  92. M. Matusiak, N. Van Opdenbosch, L. Vande Walle, J.-C. Sirard, D.-T. Kanneganti, and M. Lamkanfi, “Flagellin-induced NLRC4 phosphorylation primes the inflammasome for activation by NAIP5,” Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 5, pp. 1541–1546, 2015. View at Publisher · View at Google Scholar
  93. E. M. Kofoed and R. E. Vance, “Innate immune recognition of bacterial ligands by NAIPs determines inflammasome specificity,” Nature, vol. 477, no. 7366, pp. 592–597, 2011. View at Publisher · View at Google Scholar · View at Scopus
  94. C. B. Turley, R. E. Rupp, C. Johnson et al., “Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults,” Vaccine, vol. 29, no. 32, pp. 5145–5152, 2011. View at Publisher · View at Google Scholar · View at Scopus
  95. D. N. Taylor, J. J. Treanor, E. A. Sheldon et al., “Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response,” Vaccine, vol. 30, no. 39, pp. 5761–5769, 2012. View at Publisher · View at Google Scholar · View at Scopus
  96. E. H. Kim, J. H. Kim, R. Samivel et al., “Intralymphatic treatment of flagellin-ovalbumin mixture reduced allergic inflammation in murine model of allergic rhinitis,” Allergy, 2016. View at Publisher · View at Google Scholar
  97. R. D. Weeratna, S. R. Makinen, M. J. McCluskie, and H. L. Davis, “TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848),” Vaccine, vol. 23, no. 45, pp. 5263–5270, 2005. View at Publisher · View at Google Scholar · View at Scopus
  98. D. I. Bernstein, C. J. Harrison, M. A. Tomai, and R. L. Miller, “Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment,” Journal of Infectious Diseases, vol. 183, no. 6, pp. 844–849, 2001. View at Publisher · View at Google Scholar · View at Scopus
  99. C. J. Harrison, R. L. Miller, and D. I. Bernstein, “Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs,” Antimicrobial Agents and Chemotherapy, vol. 38, no. 9, pp. 2059–2064, 1994. View at Publisher · View at Google Scholar · View at Scopus
  100. H. Hemmi, T. Kaisho, K. Takeda, and S. Akira, “The roles of toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets,” The Journal of Immunology, vol. 170, no. 6, pp. 3059–3064, 2003. View at Publisher · View at Google Scholar · View at Scopus
  101. S. Akira and K. Takeda, “Toll-like receptor signalling,” Nature Reviews Immunology, vol. 4, no. 7, pp. 499–511, 2004. View at Publisher · View at Google Scholar · View at Scopus
  102. N. M. Shukla, S. S. Malladi, C. A. Mutz, R. Balakrishna, and S. A. David, “Structure-activity relationships in human toll-like receptor 7-active imidazoquinoline analogues,” Journal of Medicinal Chemistry, vol. 53, no. 11, pp. 4450–4465, 2010. View at Publisher · View at Google Scholar · View at Scopus
  103. S. Gnjatic, N. B. Sawhney, and N. Bhardwaj, “Toll-like receptor agonists are they good adjuvants?” Cancer Journal, vol. 16, no. 4, pp. 382–391, 2010. View at Publisher · View at Google Scholar · View at Scopus
  104. A. Iwasaki and R. Medzhitov, “Toll-like receptor control of the adaptive immune responses,” Nature Immunology, vol. 5, no. 10, pp. 987–995, 2004. View at Publisher · View at Google Scholar · View at Scopus
  105. M. Jurk, F. Heil, J. Vollmer et al., “Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848,” Nature Immunology, vol. 3, no. 6, article 499, 2002. View at Publisher · View at Google Scholar · View at Scopus
  106. K. Loré, M. R. Betts, J. M. Brenchley et al., “Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses,” The Journal of Immunology, vol. 171, no. 8, pp. 4320–4328, 2003. View at Publisher · View at Google Scholar · View at Scopus
  107. A. Le Bon, N. Etchart, C. Rossmann et al., “Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon,” Nature Immunology, vol. 4, no. 10, pp. 1009–1015, 2003. View at Publisher · View at Google Scholar · View at Scopus
  108. C. Liu, Y. Lou, G. Lizée et al., “Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice,” The Journal of Clinical Investigation, vol. 118, no. 3, pp. 1165–1175, 2008. View at Publisher · View at Google Scholar · View at Scopus
  109. G. A. Bishop, L. M. Ramirez, M. Baccam, L. K. Busch, L. K. Pederson, and M. A. Tomai, “The immune response modifier resiquimod mimics CD40-induced B cell activation,” Cellular Immunology, vol. 208, no. 1, pp. 9–17, 2001. View at Publisher · View at Google Scholar · View at Scopus
  110. C. V. Caperton and B. Berman, “Safety, efficacy, and patient acceptability of imiquimod for topical treatment of actinic keratoses,” Clinical, Cosmetic and Investigational Dermatology, vol. 4, pp. 35–40, 2011. View at Publisher · View at Google Scholar
  111. V. Oldfield, G. M. Keating, and C. M. Perry, “Imiquimod: in superficial basal cell carcinoma,” American Journal of Clinical Dermatology, vol. 6, no. 3, pp. 195–202, 2005. View at Publisher · View at Google Scholar · View at Scopus
  112. G. Micali, F. Lacarrubba, M. R. Nasca, S. Ferraro, and R. A. Schwartz, “Topical pharmacotherapy for skin cancer: part II. Clinical applications,” Journal of the American Academy of Dermatology, vol. 70, no. 6, pp. 979.e1–979.e12, 2014. View at Publisher · View at Google Scholar · View at Scopus
  113. U. R. Hengge, S. Esser, T. Schultewolter et al., “Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum,” British Journal of Dermatology, vol. 143, no. 5, pp. 1026–1031, 2000. View at Publisher · View at Google Scholar · View at Scopus
  114. T. Rosen, A. Nelson, and K. Ault, “Imiquimod cream 2.5% and 3.75% applied once daily to treat external genital warts in men,” Cutis, vol. 96, no. 4, pp. 277–282, 2015. View at Google Scholar
  115. K. E. Mark, L. Corey, T.-C. Meng et al., “Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial,” Journal of Infectious Diseases, vol. 195, no. 9, pp. 1324–1331, 2007. View at Publisher · View at Google Scholar · View at Scopus
  116. K. H. Fife, T.-C. Meng, D. G. Ferris, and P. Liu, “Effect of resiquimod 0.01% gel on lesion healing and viral shedding when applied to genital herpes lesions,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 2, pp. 477–482, 2008. View at Publisher · View at Google Scholar · View at Scopus
  117. D. H. Dockrell and G. R. Kinghorn, “Imiquimod and resiquimod as novel immunomodulators,” Journal of Antimicrobial Chemotherapy, vol. 48, no. 6, pp. 751–755, 2001. View at Publisher · View at Google Scholar · View at Scopus
  118. R. M. Prins, N. Craft, K. W. Bruhn et al., “The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity,” The Journal of Immunology, vol. 176, no. 1, pp. 157–164, 2006. View at Publisher · View at Google Scholar · View at Scopus
  119. D. Smirnov, J. J. Schmidt, J. T. Capecchi, and P. D. Wightman, “Vaccine adjuvant activity of 3m-052: an imidazoquinoline designed for local activity without systemic cytokine induction,” Vaccine, vol. 29, no. 33, pp. 5434–5442, 2011. View at Publisher · View at Google Scholar · View at Scopus
  120. D. J. Dowling, Z. Tan, Z. M. Prokopowicz et al., “The ultra-potent and selective TLR8 agonist VTX-294 activates human newborn and adult leukocytes,” PLoS ONE, vol. 8, no. 3, Article ID e58164, 2013. View at Publisher · View at Google Scholar · View at Scopus
  121. C. C. N. Wu, B. Crain, S. Yao et al., “Innate immune protection against infectious diseases by pulmonary administration of a phospholipid-conjugated TLR7 ligand,” Journal of Innate Immunity, vol. 6, no. 3, pp. 315–324, 2014. View at Publisher · View at Google Scholar · View at Scopus
  122. P. Dasari, I. C. Nicholson, G. Hodge, G. W. Dandie, and H. Zola, “Expression of toll-like receptors on B lymphocytes,” Cellular Immunology, vol. 236, no. 1-2, pp. 140–145, 2005. View at Publisher · View at Google Scholar · View at Scopus
  123. L. A. J. O'Neill, C. E. Bryant, and S. L. Doyle, “Therapeutic targeting of toll-like receptors for infectious and inflammatory diseases and cancer,” Pharmacological Reviews, vol. 61, no. 2, pp. 177–197, 2009. View at Publisher · View at Google Scholar · View at Scopus
  124. D. M. Foureau, D. W. Mielcarz, L. C. Menard et al., “TLR9-dependent induction of intestinal α-defensins by Toxoplasma gondii,” The Journal of Immunology, vol. 184, no. 12, pp. 7022–7029, 2010. View at Publisher · View at Google Scholar · View at Scopus
  125. A. M. Krieg, “CpG DNA: trigger of sepsis, mediator of protection, or both?” Scandinavian Journal of Infectious Diseases, vol. 35, no. 9, pp. 653–659, 2003. View at Publisher · View at Google Scholar · View at Scopus
  126. D. M. Klinman, “Use of CpG oligodeoxynucleotides as immunoprotective agents,” Expert Opinion on Biological Therapy, vol. 4, no. 6, pp. 937–946, 2004. View at Publisher · View at Google Scholar · View at Scopus
  127. J. Vollmer, R. Weeratna, P. Payette et al., “Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities,” European Journal of Immunology, vol. 34, no. 1, pp. 251–262, 2004. View at Publisher · View at Google Scholar · View at Scopus
  128. G. Hartmann, J. Battiany, H. Poeck et al., “Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-α induction in plasmacytoid dendritic cells,” European Journal of Immunology, vol. 33, no. 6, pp. 1633–1641, 2003. View at Publisher · View at Google Scholar · View at Scopus
  129. J. D. Marshall, E. M. Hessel, J. Gregorio et al., “Novel chimeric immunomodulatory compounds containing short CpG oligodeoxyribonucleotides have differential activities in human cells,” Nucleic Acids Research, vol. 31, no. 17, pp. 5122–5133, 2003. View at Publisher · View at Google Scholar · View at Scopus
  130. S. A. Halperin, S. Dobson, S. McNeil et al., “Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults,” Vaccine, vol. 24, no. 1, pp. 20–26, 2006. View at Publisher · View at Google Scholar · View at Scopus
  131. M. Barry and C. Cooper, “Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy,” Expert Opinion on Biological Therapy, vol. 7, no. 11, pp. 1731–1737, 2007. View at Publisher · View at Google Scholar · View at Scopus
  132. C. Schmidt, “Clinical setbacks for toll-like receptor 9 agonists in cancer,” Nature Biotechnology, vol. 25, no. 8, pp. 825–826, 2007. View at Publisher · View at Google Scholar · View at Scopus
  133. F. Ellouz, A. Adam, R. Ciorbaru, and E. Lederer, “Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives,” Biochemical and Biophysical Research Communications, vol. 59, no. 4, pp. 1317–1325, 1974. View at Publisher · View at Google Scholar · View at Scopus
  134. S. E. Girardin, I. G. Boneca, J. Viala et al., “Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection,” The Journal of Biological Chemistry, vol. 278, no. 11, pp. 8869–8872, 2003. View at Publisher · View at Google Scholar · View at Scopus
  135. K. Dzierzbicka, A. Wardowska, and P. Trzonkowski, “Recent developments in the synthesis and biological activity of muramylpeptides,” Current Medicinal Chemistry, vol. 18, no. 16, pp. 2438–2451, 2011. View at Publisher · View at Google Scholar · View at Scopus
  136. P. T. P. Kaumaya, K. C. Foy, J. Garrett et al., “Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors,” Journal of Clinical Oncology, vol. 27, no. 31, pp. 5270–5277, 2009. View at Publisher · View at Google Scholar · View at Scopus
  137. S. Lee and M. T. Nguyen, “Recent advances of vaccine adjuvants for infectious diseases,” Immune Network, vol. 15, no. 2, pp. 51–57, 2015. View at Publisher · View at Google Scholar
  138. T. Querec, S. Bennouna, S. Alkan et al., “Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity,” Journal of Experimental Medicine, vol. 203, no. 2, pp. 413–424, 2006. View at Publisher · View at Google Scholar · View at Scopus
  139. T. K. Ghosh, D. J. Mickelson, J. Fink et al., “Toll-like receptor (TLR) 2-9 agonists-induced cytokines and chemokines: I. Comparison with T cell receptor-induced responses,” Cellular Immunology, vol. 243, no. 1, pp. 48–57, 2006. View at Publisher · View at Google Scholar · View at Scopus
  140. R. P. J. Lai, M. S. Seaman, P. Tonks et al., “Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants,” PLoS ONE, vol. 7, no. 4, Article ID e35083, 2012. View at Publisher · View at Google Scholar · View at Scopus
  141. S. P. Kasturi, I. Skountzou, R. A. Albrecht et al., “Programming the magnitude and persistence of antibody responses with innate immunity,” Nature, vol. 470, no. 7335, pp. 543–550, 2011. View at Publisher · View at Google Scholar · View at Scopus
  142. G. Napolitani, A. Rinaldi, F. Bertoni, F. Sallusto, and A. Lanzavecchia, “Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells,” Nature Immunology, vol. 6, no. 8, pp. 769–776, 2005. View at Publisher · View at Google Scholar
  143. S. L. Hoffman, J. Vekemans, T. L. Richie, and P. E. Duffy, “The March toward malaria vaccines,” American Journal of Preventive Medicine, vol. 49, no. 6, supplement 4, pp. S319–S333, 2015. View at Publisher · View at Google Scholar
  144. N. Garçon, P. Chomez, and M. Van Mechelen, “GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives,” Expert Review of Vaccines, vol. 6, no. 5, pp. 723–739, 2007. View at Publisher · View at Google Scholar · View at Scopus
  145. K. E. Kester, J. F. Cummings, O. Ofori-Anyinam et al., “Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection,” Journal of Infectious Diseases, vol. 200, no. 3, pp. 337–346, 2009. View at Publisher · View at Google Scholar · View at Scopus
  146. G. Leroux-Roels, I. Leroux-Roels, F. Clement et al., “Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines: randomized, double-blind study in malaria-naïve adults,” Human Vaccines and Immunotherapeutics, vol. 10, no. 8, pp. 2211–2219, 2014. View at Publisher · View at Google Scholar · View at Scopus
  147. D. M. Harper, E. L. Franco, C. Wheeler et al., “Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial,” The Lancet, vol. 364, no. 9447, pp. 1757–1765, 2004. View at Publisher · View at Google Scholar · View at Scopus
  148. J. Paavonen, D. Jenkins, F. X. Bosch et al., “Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial,” The Lancet, vol. 369, no. 9580, pp. 2161–2170, 2007. View at Publisher · View at Google Scholar · View at Scopus
  149. S. Thoelen, N. De Clercq, and N. Tornieporth, “A prophylactic hepatitis B vaccine with a novel adjuvant system,” Vaccine, vol. 19, no. 17–19, pp. 2400–2403, 2001. View at Publisher · View at Google Scholar · View at Scopus
  150. M. M. Levine, “Immunization against bacterial diseases of the intestine,” Journal of Pediatric Gastroenterology and Nutrition, vol. 31, no. 4, pp. 336–355, 2000. View at Publisher · View at Google Scholar · View at Scopus
  151. A. Z. Kapikian, Y. Hoshino, R. M. Chanock, and I. Perez-Schael, “Efficacy of a quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children,” Journal of Infectious Diseases, vol. 174, supplement 1, pp. S65–S72, 1996. View at Publisher · View at Google Scholar · View at Scopus
  152. R. B. Belshe, P. M. Mendelman, J. Treanor et al., “The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children,” The New England Journal of Medicine, vol. 338, no. 20, pp. 1405–1412, 1998. View at Publisher · View at Google Scholar · View at Scopus
  153. H. Savelkoul, V. Ferro, M. Strioga, and V. Schijns, “Choice and design of adjuvants for parenteral and mucosal vaccines,” Vaccines, vol. 3, no. 1, pp. 148–171, 2015. View at Publisher · View at Google Scholar
  154. B. L. Dickinson and J. D. Clements, “Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity,” Infection and Immunity, vol. 63, no. 5, pp. 1617–1623, 1995. View at Google Scholar · View at Scopus
  155. G. Douce, C. Turcotte, I. Cropley et al., “Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 5, pp. 1644–1648, 1995. View at Publisher · View at Google Scholar · View at Scopus
  156. J. D. Barackman, G. Ott, S. Pine, and D. T. O'Hagan, “Oral administration of influenza vaccine in combination with the adjuvants LT-K63 and LT-R72 induces potent immune responses comparable to or stronger than traditional intramuscular immunization,” Clinical and Diagnostic Laboratory Immunology, vol. 8, no. 3, pp. 652–657, 2001. View at Publisher · View at Google Scholar · View at Scopus
  157. M. Marchetti, M. Rossi, V. Giannelli et al., “Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant,” Vaccine, vol. 16, no. 1, pp. 33–37, 1998. View at Publisher · View at Google Scholar · View at Scopus
  158. D. O'Hagan, C. Goldbeck, M. Ugozzoli, G. Ott, and R. L. Burke, “Intranasal immunization with recombinant gD2 reduces disease severity and mortality following genital challenge with herpes simplex virus type 2 in guinea pigs,” Vaccine, vol. 17, no. 18, pp. 2229–2236, 1999. View at Publisher · View at Google Scholar · View at Scopus
  159. H. Jakobsen, D. Schulz, M. Pizza, R. Rappuoli, and I. Jónsdóttir, “Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections,” Infection and Immunity, vol. 67, no. 11, pp. 5892–5897, 1999. View at Google Scholar · View at Scopus
  160. E. J. Ryan, E. Mcneela, G. A. Murphy et al., “Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells,” Infection and Immunity, vol. 67, no. 12, pp. 6270–6280, 1999. View at Google Scholar · View at Scopus
  161. J. H. Rhee, S. E. Lee, and S. Y. Kim, “Mucosal vaccine adjuvants update,” Clinical and Experimental Vaccine Research, vol. 1, no. 1, pp. 50–63, 2012. View at Publisher · View at Google Scholar
  162. M. C. Gagliardi, F. Sallusto, M. Marinaro et al., “Cholera toxin induces maturation of human dendritic cells and licences them for Th2 priming,” European Journal of Immunology, vol. 30, no. 8, pp. 2394–2403, 2000. View at Publisher · View at Google Scholar
  163. D. Y. Bargieri, D. S. Rosa, M. A. S. Lasaro, L. C. S. Ferreira, I. S. Soares, and M. M. Rodrigues, “Adjuvant requirement for successful immunization with recombinant derivatives of Plasmodium vivax merozoite surface protein-1 delivered via the intranasal route,” Memorias do Instituto Oswaldo Cruz, vol. 102, no. 3, pp. 313–317, 2007. View at Publisher · View at Google Scholar · View at Scopus
  164. D. Ruane, A. Chorny, H. Lee et al., “Microbiota regulate the ability of lung dendritic cells to induce IgA class-switch recombination and generate protective gastrointestinal immune responses,” The Journal of Experimental Medicine, vol. 213, no. 1, pp. 53–73, 2016. View at Publisher · View at Google Scholar
  165. S. A. Moschos, V. W. Bramwell, S. Somavarapu, and H. O. Alpar, “Adjuvant synergy: the effects of nasal coadministration of adjuvants,” Immunology and Cell Biology, vol. 82, no. 6, pp. 628–637, 2004. View at Publisher · View at Google Scholar · View at Scopus
  166. E. A. McNeela, I. Jabbal-Gill, L. Illum et al., “Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan,” Vaccine, vol. 22, no. 8, pp. 909–914, 2004. View at Publisher · View at Google Scholar · View at Scopus
  167. K. H. G. Mills, C. Cosgrove, E. A. McNeela et al., “Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin A,” Infection and Immunity, vol. 71, no. 2, pp. 726–732, 2003. View at Publisher · View at Google Scholar · View at Scopus
  168. Y. Gong, L. Tao, F. Wang et al., “Chitosan as an adjuvant for a Helicobacter pylori therapeutic vaccine,” Molecular Medicine Reports, vol. 12, no. 3, pp. 4123–4132, 2015. View at Publisher · View at Google Scholar · View at Scopus
  169. F. Verdier, “Non-clinical vaccine safety assessment,” Toxicology, vol. 174, no. 1, pp. 37–43, 2002. View at Publisher · View at Google Scholar · View at Scopus
  170. M. J. Brennan, “The US food and drug administration provides a pathway for licensing vaccines for global diseases,” PLoS Medicine, vol. 6, no. 7, Article ID e1000095, 2009. View at Publisher · View at Google Scholar · View at Scopus
  171. T. E. M. Agency, Guideline on Adjuvants in Vaccines, T. E. M. Agency, London, UK, 2005.